The aim of this study was preparation and evaluation of ciprofloxacin-containing minitablets for ocular use, in an attempt to obtain prolonged and controlled drug release to the anterior eye segment. Following initial studies on ciprofloxacin powder, it was formulated into ocular minitablets. For this purpose, ciprofloxacin along with various amounts of different sustained release cellulose de...

The aim of this study is to formulate a novel ophthalmic nanosuspension (ONS), an alternative carrier system to traditional colloidal carriers for controlled release (CR) of acyclovir (ACV). In the present study, ONS is employed to avoid some of major disadvantages of colloidal carriers systems such as instability in cul de sac and short half life by increasing efficiency of drug encapsulation ...

Chitosan with excellent biodegradable and biocompatible characteristics has received attention as an oral drug delivery vehicle for controlled-release formulations. In this study an enteric-coated capsule containing theophylline-chitosan beads based on 23 factorial designs was prepared as a colon drug delivery system. The theophylline-chitosan gel beads were formulated by adding the drug-contai...

The aim of this study was preparation and evaluation of ciprofloxacin-containing minitablets for ocular use, in an attempt to obtain prolonged and controlled drug release to the anterior eye segment. Following initial studies on ciprofloxacin powder, it was formulated into ocular minitablets. For this purpose, ciprofloxacin along with various amounts of different sustained release cellulose de...

The timing of neurotransmitter release from neurons can be modulated by many presynaptic mechanisms. The retina uses synaptic ribbons to mediate slow graded glutamate release from bipolar cells that carry photoreceptor inputs. However, many inhibitory amacrine cells, which modulate bipolar cell output, spike and do not have ribbons for graded release. Despite this, slow glutamate release from b...

Patients undergoing long-term therapy for PD often experience motor fluctuations and nocturnal disturbances. In a post-hoc analysis, we explored effects of ropinirole prolonged release on sleep, night-time awakenings, and "on" time over 24 hours. Patients with advanced PD suboptimally controlled with L-dopa were randomized to adjunctive ropinirole prolonged release (2-24 mg/day) or placebo for ...